More Support for Genetic Testing of Hepatitis C Patients | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Telaprevir Shows Promise in Those Co-Infected with Hepatitis C and HIV

Back to News Homepage
Next

Preventing Re-infection With Hep C Post-Transplant

More Support for Genetic Testing of Hepatitis C Patients

The Editors at Hepatitis Central
March 16, 2011

Print this page

A large retrospective study further confirms that the IL28B genotype predicts both early and sustained responses to interferon-based Hepatitis C treatment.

IL28B Genotype Predicts Treatment Response in Chronic Hepatitis C

By: MARY ANN MOON, Internal Medicine News Digital Network

Patients with treatment-naive chronic hepatitis C virus infection who carry the rs12979860 C/C or rs8099917 T/T polymorphisms in the region of the IL28B gene are more likely than are noncarriers to show an early virologic response, as well as a sustained virologic response, to interferon-based therapy, Dr. Albert Stättermayer and his colleagues reported in the April issue of Clinical Gastroenterology and Hepatology.

Currently, the IL28B status of patients is obtained routinely and is used to predict the likelihood of their response to combined peginterferon/ribavirin therapy.

Continue reading this entire article:
http://www.internalmedicinenews.com/news/gastroenterology/single-article/il28b-genotype-predicts-treatment-response-in-chronic-hepatitis-c/ee1b70a539.html

No Comments - be the first!
Share
Share
Previous

Telaprevir Shows Promise in Those Co-Infected with Hepatitis C and HIV

Back to News Homepage
Next

Preventing Re-infection With Hep C Post-Transplant

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.